Search NLS News

Pharmaceutical ingredients have been detected in the environment – on every continent. The same properties that make pharmaceuticals effective increase the risk of undesired effects in the environment. Pharmaceutical residues in the environment are a growing concern. Active pharmaceutical ingredients (APIs) are a wide and diverse group of compounds. They are designed to cure, treat, […]

Valo Therapeutics has announced a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study. ValoTx’s PeptiCRAd-1 combines the power of a tumor-specific adenovirus (expressing immune-stimulatory molecules CD40L and OX40L) with immunogenic tumor peptides derived from NY-ESO-1 and MAGE-A3 proteins thereby generating tumor-specific, cytotoxic T-cells that […]

The company has been selected, for the second year in a row, to Cleantech Group’s list if companies taking action on the climate crisis. “It’s a recognition of our ongoing quest to deliver innovative solutions that can help all of us find cleaner, less wasteful ways to live, and to put society back on a […]

This year’s theme was ‘Stand Up for Science’ but the world’s largest biotechnology conference covers so much more and attracted companies, investors and policy makers from around the globe – including, of course, those representing the Nordics. Although partnering is the main reason why most companies’ management team attend the event, BIO is also the […]

Eclipsed by the oil and gas industry, Norwegian life science has nonetheless grown to become an important export industry. Successes have been built on the pioneers of pharmaceutical innovations in the 1950s and 60s, such as Nycomed which is part of GE Healthcare today – a sole contributor of 2 percent of the Norwegian mainland […]

This year’s International Cancer Cluster Showcase featured 20 emerging oncology companies that presented their recent innovations, partnering and investment opportunities. The International Cancer Cluster Showcase (ICCS) is a satellite event to BIO International Convention and was arranged on 5 June 2023 in Boston, USA. This was the 12th edition of the ICCS and this year […]

The FDA Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from the Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI 100 mg/mL intravenous injection for the treatment of Alzheimer’s disease. LEQEMBI received Accelerated approval from the FDA for the treatment of early Alzheimer’s disease on […]

Novartis has entered into an agreement to acquire Chinook Therapeutics, a Seattle, WA, based clinical stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed deal, which is subject to customary closing conditions, is fully in line with Novartis strategy to focus on innovative medicines and will […]

Zerion Pharma has announced the publication of joint experimental work on its Dispersome technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers. The work behind the publications originated from two partnership projects, one with Bayer AG and one with Novartis Pharma AG. The former can be accessed here and showcases the […]

The University of Copenhagen is the first Danish university to invest in a company based on its own research in unique collaboration with a venture fund. On April 11th 2023, the company GutCRINE ApS received an initial financing of 4 million DKK to begin development of a completely new class of biological medicines, so-called pharmabiotics. […]